NCT05744128View on ClinicalTrials.gov

CD8 Minibody Repeatability Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
MelanomaRenal Cell Carcinoma
Interventions
BIOLOGICAL

Zirconium 89Zr crefmirlimab berdoxam

Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.

Trial Locations (1)

HU16 5JQ

Castle Hill Hospital, Hull

Sponsors

Lead Sponsor

ImaginAb, Inc.
All Listed Sponsors
collaborator

University of Hull

OTHER

lead

ImaginAb, Inc.

INDUSTRY